Index > Vol. 85/2005 > Iss. 3/May > pp. 236-239 > Abstract
Letter to the Editor

Comparison of Tazarotene 0.1% Gel Plus Petrolatum Once Daily Versus Calcipotriol 0.005% Ointment Twice Daily in the Treatment of Plaque Psoriasis

doi: 10.1080/00015550510027405

Abstract:

Tazarotene and calcipotriol are both effective in the treatment of psoriasis. An investigator-blind, bilateral comparison of 44 lesion pairs in 19 patients was conducted to evaluate the efficacy, side effects and duration of therapeutic effects of once-daily tazarotene 0.1% gel plus petrolatum with twice-daily calcipotriol 0.005% ointment in plaque psoriasis. It consisted of a 12-week treatment phase, followed by a 4-week post-treatment observation phase. At the end of the treatment phase, tazarotene-petrolatum was as effective as calcipotriol in both objective and subjective overall efficacy assessment. Calcipotriol had a significantly greater effect in reducing erythema than tazarotene-petrolatum at weeks 2&emdash;8. At week 16, tazarotene-petrolatum demonstrated a significantly better maintenance effect in all parameters. Local irritation was noted only in tazarotene-petrolatum-treated lesions. Once-daily tazarotene 0.1% gel plus petrolatum was as effective as twice-daily calcipotriol 0.005% ointment in the treatment of plaque psoriasis, but had a better maintenance effect after the cessation of therapy.

Key words:

calcipotriol, psoriasis, tazarotene

References:

  1. Koo, J, Lebwohl, M. Duration of remission of psoriasis therapies. J Am Acad Dermatol, 1999; 41: 51–59
  2. Bowman, P. H, Maloney, J. E, Koo, J. Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study. J Am Acad Dermatol, 2002; 46: 907–913
  3. Veien, N. K, Bjerke, J. R, Rossmann-Ringdahl, I, Jakobsen, H. B. Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double-blind trial. Br J Dermatol, 1997; 137: 581–586
  4. Guenther, L. C, Poulin, Y. P, Pariser, D. M. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. Clin Ther, 2000; 22: 1225–1238
  5. Schiener, R, Behrens-Williams, S. C, Pillekamp, H, Kaskel, P, Peter, R. U, Kerscher, M. Calcipotriol vs. tazarotene as combination therapy with narrowband ultraviolet B (311 nm): efficacy in patients with severe psoriasis. Br J Dermatol, 2000; 143: 1275–1278
  6. Tanghetti, E. A. An observation study evaluating the efficacy of tazarotene plus corticosteroid in treating plaque psoriasis in patients switched from treatment with calcipotriene±corticosteroid. Cutis, 2000; 66: 12–18
  7. David, C. Evaluating the potential clinical benefits of switching patients with plaque psoriasis from calcipotriene to tazarotene treatment. Cutis, 2000; 66: 19–24
  8. Witman, P. M. Topical therapies for localized psoriasis. Mayo Clin Proc, 2001; 76: 943–949
  9. Tanghetti, E. A. An observation study evaluating the treatment of plaque psoriasis with tazarotene gels, alone and with an emollient and/or corticosteroid. Cutis, 2000; 66: 4–11
  10. Weinstein, G. D, Krueger, G. G, Lowe, N. J, Duvic, M, Friedman, D. J, Jegasothy, B. V. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol, 1997; 37: 85–92 et al.
  11. Gollnick, H. P, Finzi, A. F, Marks, R, Barker, J. N, Jansen, C, Revuz, J. Optimising the use of tazarotene in clinical practice: consensus statement from the European Advisory Panel for tazarotene (Zorac). Dermatology, 1999; 199: 40–46 et al.
  12. Salmhofer, W, Maier, H, Soyer, H. P, Honigsmann, H, Hodl, S. Double-blind, placebo-controlled, randomized, right–left study comparing calcipotriol monotherapy with a combined treatment of calcipotriol and diflucortolone valerate in chronic plaque psoriasis. Acta Derm Venereol, 2000; 211: 5–8
  13. Lebwohl, M, Ast, E, Callen, J. P, Cullen, S. I, Hong, S. R, Kulp-Shorten, C. L. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol, 1998; 38: 705–711 et al.
  14. Lebwohl, M, Ali, S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol, 2001; 45: 487–498
  15. Guenther, L, Cambazard, F, Van de Kerkhof, P. C. M, Snellman, E, Kragballe, J, Chu, A. C. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol, 2002; 147: 316–323 et al.
  16. Molin, L, Cutler, T. P, Helander, I, Nyfors, B, Downes, N. Comparative efficacy of calcipotriol (MC 930) cream and betamethasone 17-valerate cream in the treatment of chronic psoriasis. A randomized, double-blind, parallel group multicentre study. Br J Dermatol, 1997; 136: 89–93
  17. Kullavanijaya, P, Gritiyarangsan, P, Huiprasert, P, Leenutaphong, V. Treatment of psoriasis vulgaris with topical vitamin D analogue (calcipotriol): open multicenter study. J Med Assoc Thai, 1999; 82: 874–876
"